Tricia Plouf Sells 1,000 Shares of Trupanion Inc (TRUP) Stock
Trupanion Inc (NYSE:TRUP) CFO Tricia Plouf sold 1,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $32.11, for a total transaction of $32,110.00. Following the sale, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $449,540. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Trupanion Inc (NYSE TRUP) traded down $0.03 during trading on Friday, reaching $29.95. 66,610 shares of the company traded hands, compared to its average volume of 229,598. Trupanion Inc has a one year low of $13.71 and a one year high of $33.00.
Trupanion (NYSE:TRUP) last announced its quarterly earnings results on Thursday, November 2nd. The financial services provider reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.04. The business had revenue of $63.12 million for the quarter, compared to analysts’ expectations of $61.44 million. Trupanion had a net margin of 0.71% and a return on equity of 3.57%. The business’s quarterly revenue was up 30.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.06) EPS.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Trupanion from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Wednesday, October 4th. BidaskClub downgraded shares of Trupanion from a “buy” rating to a “hold” rating in a research report on Friday. Canaccord Genuity reissued a “buy” rating and set a $35.00 price objective (up previously from $29.00) on shares of Trupanion in a research report on Tuesday, October 31st. Cowen and Company reissued an “outperform” rating and set a $28.00 price objective (up previously from $19.00) on shares of Trupanion in a research report on Wednesday, August 2nd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $24.00 price objective (up previously from $18.00) on shares of Trupanion in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $28.83.
A number of hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its stake in Trupanion by 173.7% in the 3rd quarter. Wells Fargo & Company MN now owns 30,819 shares of the financial services provider’s stock worth $813,000 after purchasing an additional 19,558 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Trupanion in the 3rd quarter worth $143,000. EAM Investors LLC raised its position in shares of Trupanion by 113.9% during the 3rd quarter. EAM Investors LLC now owns 94,836 shares of the financial services provider’s stock valued at $2,505,000 after buying an additional 50,507 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Trupanion by 3.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 77,182 shares of the financial services provider’s stock valued at $2,038,000 after buying an additional 2,382 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Trupanion during the 3rd quarter valued at about $395,000.
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
Receive News & Ratings for Trupanion Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.